

22 predictive value towards this goal, above and beyond existing clinical risk models. The current systematic review aims to answer
23 the question "Do MRI markers predict future cognitive functioning in pediatric brain tu 23 the question "Do MRI markers predict future cognitive functioning in pediatric brain tumour survivors?". Studies of pediatric brain tumour patients which test the value of MRI variables in predicting later neuropsycholo 24 brain tumour patients which test the value of MRI variables in predicting later neuropsychological outcomes were searched up to
25 July 2022. Only included were studies where MRI scans were acquired at an earlier timepo 25 July 2022. Only included were studies where MRI scans were acquired at an earlier timepoint and used to predict a child's performance on cognitive tests at a later timepoint. Surprisingly few studies were identified by 26 performance on cognitive tests at a later timepoint. Surprisingly few studies were identified by the search process which
27 specifically investigated MRI measures of cerebellar and white matter damage as features in pr 27 specifically investigated MRI measures of cerebellar and white matter damage as features in predicting cognitive outcomes.
28 However, the important finding of this review is that the current literature is limited and t 28 However, the important finding of this review is that the current literature is limited and those identified had small sample sizes
29 and were rated as poor quality for the purposes of prediction. Overall, current find 29 and were rated as poor quality for the purposes of prediction. Overall, current findings are at high risk of bias and thus the quality
30 and impact of conclusions are limited. Given the significant impact for this clin 30 and impact of conclusions are limited. Given the significant impact for this clinical population that predictive models would enable, the current review affirms the need for a 'call to action' for medical imaging resear ³¹enable, the current review affirms the need for a 'call to action' for medical imaging researchers in pediatric neuro-oncology.

³²**Keywords: MRI, neuropsychology outcomes, prediction, Brain Tumour, children**

-
- 34

³⁵**Introduction**

³⁶*Individual Outcomes for Childhood Brain Tumour Patients*

37 Survival from cancer in childhood has seen great improvement in recent decades [1]. Consequently, there is a large and increasing population of adult survivors of childhood cancers [1, 2], with approximately 1 in 530 yo 38 population of adult survivors of childhood cancers [1, 2], with approximately 1 in 530 young adults between the ages of 20 and 39 being a survivor of childhood cancer [3]. This is especially true in pediatric brain tumo 39 being a survivor of childhood cancer [3]. This is especially true in pediatric brain tumours, the most common solid tumours in children (roughly 20%) [4], where survival is now estimated at around 95% for cerebellar pil 40children (roughly 20%) [4], where survival is now estimated at around 95% for cerebellar pilocytic astrocytoma, and 60-80% for medulloblastoma [5-8]. Thus, there is an ever increasing need to focus on ensuring quality of

41 medulloblastoma [5-8]. Thus, there is an ever increasing need to focus on ensuring quality of life for the future of these children.
42 Many children with brain tumours experience neurocognitive effects at some point in 42 Many children with brain tumours experience neurocognitive effects at some point in their disease course, resulting in dysfunction
43 in domains of cognition, emotion, and behaviour. The estimated risk for children with ⁴³in domains of cognition, emotion, and behaviour. The estimated risk for children with brain tumours of having emotional,
⁴⁴ psychosocial, and attention problems are 15%, 12% and 12% respectively, according to a recen 44 psychosocial, and attention problems are 15%, 12% and 12% respectively, according to a recent meta-analysis [9]. Even at 10-
45 year survival, these patients still demonstrate neuropsychological and psychosocial impairm 45 year survival, these patients still demonstrate neuropsychological and psychosocial impairment across multiple domains [10].
46 Performance over time demonstrates an inability to acquire new skills and cognitive abiliti 46 Performance over time demonstrates an inability to acquire new skills and cognitive abilities at the same rate as healthy peers of the same age, rather than a loss of previously acquired abilities [11]. This may explain 47 the same age, rather than a loss of previously acquired abilities [11]. This may explain why these difficulties are likely to persist
48 long-term and are non-transient. The number of post-cancer life-years is much grea 18 long-term and are non-transient. The number of post-cancer life-years is much greater for pediatric rather than adult survivors, and
19 these years include numerous important milestones such as education and interperson these years include numerous important milestones such as education and interpersonal relationship development [12]. Long-term
50 difficulties are likely to profoundly affect participation for these children, at home, scho 50 difficulties are likely to profoundly affect participation for these children, at home, school and later in the workplace, likely
51 resulting in poorer long-term educational and employment outcomes [13, 14]. This resul 51 resulting in poorer long-term educational and employment outcomes [13, 14]. This results in persistent burden for families and
52 healthcare systems [15]. Whilst survival must always be the utmost priority, research aim 52 healthcare systems [15]. Whilst survival must always be the utmost priority, research aimed at limiting this cognitive morbidity in this group is now needed to ensure likelihood of reaching their potential, despite thei this group is now needed to ensure likelihood of reaching their potential, despite their illness [16].

54 Whilst disease and treatment will inevitably place all pediatric brain tumour patients at some level of risk for poor cognitive outcomes, knowing individualised risk at the patient level, an estimate of the severity of 55 outcomes, knowing individualised risk at the patient level, an estimate of the severity of difficulties they will face, and the specific
56 domains that are likely to be impacted, will influence clinical practice. There 56 domains that are likely to be impacted, will influence clinical practice. There is significant variability in outcomes at the individual patient-level, but this is currently understudied [15]. Person-centred analytical 57 individual patient-level, but this is currently understudied [15]. Person-centred analytical approaches across a large longitudinal sample of paediatric brain tumour patients, show distinct classes / phenotypes with uni 58 sample of paediatric brain tumour patients, show distinct classes / phenotypes with unique profiles in social, cognitive, and attentional difficulties over time [17]. Similar subgroups have been identified across cross-59 attentional difficulties over time [17]. Similar subgroups have been identified across cross-sectional neuropsychological data in
50 pediatric brain tumour patients [18]. Further research is needed to translate this int 50 pediatric brain tumour patients [18]. Further research is needed to translate this into further individualised models of risk and resilience, for use in clinical settings. resilience, for use in clinical settings.

⁶²*Clinical Benefits from Prediction of Cognitive Outcomes*

53 Prediction of individual-level neurocognitive outcomes would enable timely and tailored input from school and allied health services, promoting outcomes for these children, with limited healthcare resources being effici 54 services, promoting outcomes for these children, with limited healthcare resources being efficiently prioritised for those most at risk. It would also help healthcare professionals prepare patients for these difficultie 55 risk. It would also help healthcare professionals prepare patients for these difficulties and help reduce uncertainty over the future
56 for families. Children who are undergoing treatment, would also clinically benefit for families. Children who are undergoing treatment, would also clinically benefit from predictive research for cognitive morbidities. In children where treatment of their brain tumour is more difficult, adjuvant therapy m ⁵⁷ morbidities. In children where treatment of their brain tumour is more difficult, adjuvant therapy may include radiotherapy, which
⁵⁸ is known to have significant impact on a child's neurodevelopment. This is due to ⁵⁸is known to have significant impact on a child's neurodevelopment. This is due to brain injury from the primary and secondary
⁵⁹effects of radiotherapy, especially in paediatrics where there is specific vulnerability ⁵⁹ effects of radiotherapy, especially in paediatrics where there is specific vulnerability (e.g., due to younger children not yet having
⁷⁰ reached peak myelin maturity) [19, 20]. Whilst developments in treatment have 70 reached peak myelin maturity) [19, 20]. Whilst developments in treatment have mitigated some risk of neurocognitive toxicity
71 (e.g. proton beam radiotherapy [21]), there is still need for clinicians to make decisions 71 (e.g. proton beam radiotherapy [21]), there is still need for clinicians to make decisions about treatment strategy to further reduce
72 risk to a child's neurocognitive development, using existing disease and age relat 72 risk to a child's neurocognitive development, using existing disease and age related risk factors [19, 20]. More accurate prediction
73 of individual-level risk of cognitive morbidity (even across domain and severity), 73 of individual-level risk of cognitive morbidity (even across domain and severity), would enable clinicians to further adapt and personalise treatment schedules with a greater focus on risk to quality-of-life whilst main 74 personalise treatment schedules with a greater focus on risk to quality-of-life whilst maintaining efficacy in treating disease [22].
75 Overall, there is clinical benefit for a range of patients in knowing individualis ⁷⁵Overall, there is clinical benefit for a range of patients in knowing individualised prediction of neurocognitive outcomes.

⁷⁶*Predicting Cognitive Outcomes* 77 There are many established risk factors for poor long-term neuropsychological outcome that need to be understood to provide a
78 comprehensive risk profile at the individual child level [23]. Recent neurodevelopmental m 78 comprehensive risk profile at the individual child level [23]. Recent neurodevelopmental models based on known risk factors have
79 been proposed to explain outcomes for brain tumour survivors, specifically in medullobl 79 been proposed to explain outcomes for brain tumour survivors, specifically in medulloblastoma [24-26], taking into consideration
30 the complex disease-, treatment- and host-related factors that may influence these outc 80 the complex disease-, treatment- and host-related factors that may influence these outcomes. Many aspects can result in neurodevelopmental insults to the developing brain which may explain and underpin these neurobehavi 81 neurodevelopmental insults to the developing brain which may explain and underpin these neurobehavioral morbidities [27, 28] and thus are significant risk factors for these poor outcomes [23]. These range from physical 82 and thus are significant risk factors for these poor outcomes [23]. These range from physical factors such as treatment effects (i.e. 33 resection and/or adjuvant therapy [19, 29]) and individual differences (i.e. age a 83 resection and/or adjuvant therapy [19, 29]) and individual differences (i.e. age at diagnosis [29], cognitive reserve), but also
84 psychological factors (i.e. Early Childhood Adversity, threat exposure) and environment 84 psychological factors (i.e. Early Childhood Adversity, threat exposure) and environmental factors (i.e. Socioeconomic Status (SES) and social support) [27]. See [23] for a model of cognitive risk in pediatric brain tumo 85 (SES) and social support) [27]. See [23] for a model of cognitive risk in pediatric brain tumour survivors. Essentially, neurocognitive outcomes are complex and are dependent on several interacting factors [12]. neurocognitive outcomes are complex and are dependent on several interacting factors [12].

87 Risk-based and exposure-related guidelines and models have been developed to manage these neurocognitive late-effects of pediatric brain tumours [23, 30]. Neurobehavioral morbidities are predicted by clinical variables pediatric brain tumours [23, 30]. Neurobehavioral morbidities are predicted by clinical variables such as radiotherapy,

89 chemotherapy, neurosurgery, and parental education but less-so age at diagnosis, gender, or time since diagnosis [12, 13, 19, 31-
80 34]. The Neurological Predictor Scale (NPS) was designed as an ordinal scale to captur

9034]. The Neurological Predictor Scale (NPS) was designed as an ordinal scale to capture the cumulative effect of some of these risk factors on outcomes, and somewhat predicts IQ, adaptive functioning and processing speed

91 risk factors on outcomes, and somewhat predicts IQ, adaptive functioning and processing speed and working memory, at both 92 short- and long-term follow-up [33, 35-38]. This cumulative measure captures unique variance, 92 short- and long-term follow-up [33, 35-38]. This cumulative measure captures unique variance, above and beyond the individual predictors.

predictors.

⁹⁴*MRI as a Novel Predictor of Outcomes*

95 MRI measures are likely to be a good proxy of the burden of brain tumours and their treatment thus, are likely to be predictive of cognitive impairment at the individual patient-level. Qualitative reporting of MRI does For experiment at the individual patient-level. Qualitative reporting of MRI does in fact predict outcomes, with brainstem

For invasion, midline location of the tumour, and tumour type predicting post-operative cerebellar 97 invasion, midline location of the tumour, and tumour type predicting post-operative cerebellar mutism syndrome, a (typically)
98 transient, neurological morbidity seen in this population [39]. Quantitative alterations t 98 transient, neurological morbidity seen in this population [39]. Quantitative alterations to the brain's structure and function, specifically microstructural changes to the white matter (WM) of the brain, during the deve 99 specifically microstructural changes to the white matter (WM) of the brain, during the developmental period, could be the common neuroanatomical substrate of these outcomes [24, 26]. See [40] and [22] for a review of MR 00 common neuroanatomical substrate of these outcomes [24, 26]. See [40] and [22] for a review of MRI in pediatric brain tumours.
01 Recent successes and interest in using MRI to predict neurodevelopmental outcomes in prem 01 Recent successes and interest in using MRI to predict neurodevelopmental outcomes in premature infants [41], or even decline in
02 neurocognitive functioning in older adults [42] highlights the potential opportunities o 02 neurocognitive functioning in older adults [42] highlights the potential opportunities offered by MRI in this space. Therefore,

03 magnetic resonance imaging (MRI) is likely to provide highly relevant features which pr 03 magnetic resonance imaging (MRI) is likely to provide highly relevant features which provide 'added-value' in predicting
04 outcomes beyond clinical risk factors alone. outcomes beyond clinical risk factors alone.

05 A key consideration, however, is the timing of the MRI used to predict these outcomes. The MRI used for prediction needs to be early enough in the disease course and non-contemporaneous from the later, outcome of intere 06 early enough in the disease course and non-contemporaneous from the later, outcome of interest. There is currently no consensus
07 on the optimal timing of MRI with which to make such a prediction. This systematic revie 07 on the optimal timing of MRI with which to make such a prediction. This systematic review specifically investigates existing
08 literature using MRI scans, taken at any point in the disease course, to predict non-contem ⁰⁸literature using MRI scans, taken at any point in the disease course, to predict non-contemporaneous, later neuropsychological outcomes in survivors of pediatric brain tumours.

10 Whilst there is existing literature of existing established clinical predictors of cognitive late effects in this population, this review
11 aims to assess studies using MRI as a predictive modality, with the goal of as 11 aims to assess studies using MRI as a predictive modality, with the goal of assessing whether quantitative analysis of MRI
12 provides 'added-value' in these risk models.

provides 'added-value' in these risk models.

13 **Method**
14 **We cond**

14 We conducted this systematic review in accordance with Preferred Reporting Items for Systematic Review and Meta-Analysis (PRIMSA) guidelines [43], an overview of which is reported in Figure 1. Initially, a limited searc

15 (PRIMSA) guidelines [43], an overview of which is reported in Figure 1. Initially, a limited search of the Web of Science database
16 was undertaken in June 2022 for the purpose of refining the search terms. Due to the

16 was undertaken in June 2022 for the purpose of refining the search terms. Due to the wide-ranging classifications of central 17 nervous system (CNS) tumours, we only used terms pertaining to the most common paediatric h

17 nervous system (CNS) tumours, we only used terms pertaining to the most common paediatric histological diagnoses accounting
18 for 85% of total incidence rates (Central Brain Tumour Registry of United States, 2014-2018

18 for 85% of total incidence rates (Central Brain Tumour Registry of United States, 2014-2018 [44]). Based on our initial search, we pre-registered our review protocol through the International Prospective Register of Sys 19 pre-registered our review protocol through the International Prospective Register of Systematic Reviews (PROSPERO) database
20 (registration number CRD42022343161).

²⁰(registration number CRD42022343161).

21 A comprehensive search of Embase, MEDLINE, PsycINFO, Scopus and Web of Science was conducted in July 2022 using the
22 designed search, resulting in 8,632 records. Minor alterations were made to the search terms for eac 22 designed search, resulting in 8,632 records. Minor alterations were made to the search terms for each database to account for
23 differing Boolean operators. Additionally, we also searched the Open Science Framework (OS 23 differing Boolean operators. Additionally, we also searched the Open Science Framework (OSF) preprints archive for relevant 24 articles that had not otherwise appeared as published texts in our main search. We included 24 articles that had not otherwise appeared as published texts in our main search. We included any longitudinal study concerning
25 patients diagnosed with a brain tumour before the age of 18, who had MRI data that clearly 25 patients diagnosed with a brain tumour before the age of 18, who had MRI data that clearly preceded an age-appropriate,
26 standardised test of cognitive ability (e.g., WISC-V). Central to our main research aim, we incl 26 standardised test of cognitive ability (e.g., WISC-V). Central to our main research aim, we included those studies that explicitly reported an association between future cognitive outcomes based on prior MRI. Meta-analy 27 reported an association between future cognitive outcomes based on prior MRI. Meta-analyses and literature reviews that did not
28 report new data were excluded, however, reference lists of relevant papers were searched 28 report new data were excluded, however, reference lists of relevant papers were searched for additional studies of interest. Search
29 results were not restricted by publication date but were limited to those written in 29 results were not restricted by publication date but were limited to those written in English. In addition to our pre-registered
30 exclusion criteria, we also excluded patients with neurofibromatosis, tuberous sclerosis 30 exclusion criteria, we also excluded patients with neurofibromatosis, tuberous sclerosis, or acute lymphoblastic leukaemia as these
31 were considered significant confounds for predicting cognitive outcomes. We also exc 31 were considered significant confounds for predicting cognitive outcomes. We also excluded non-peer reviewed articles, such as conference abstracts and theses. Inclusion/exclusion criteria are further detailed in Table 1

conference abstracts and theses. Inclusion/exclusion criteria are further detailed in Table 1.

Table 1. Inclusion and exclusion criteria for identifying publications for the systematic review

• Written in English

33
34

34 Identified records were first imported into MS Excel and duplicates removed. Following a short pilot, two independent reviewers (CD + DGK) screened the titles and abstracts of all the identified papers against the inclu ³⁵(CD + DGK) screened the titles and abstracts of all the identified papers against the inclusion criteria. Full texts of suitable papers 36 were subsequently retrieved and screened by both reviewers for final inclusion in the review. For completeness, we also reviewed
37 the reference lists and citations of those papers marked for inclusion for additional s 37 the reference lists and citations of those papers marked for inclusion for additional studies that may have been missed. At each stage of the process, disagreements were discussed until a consensus was met. Per our pre-38 stage of the process, disagreements were discussed until a consensus was met. Per our pre-registration, data extraction was completed by one reviewer (DGK), whilst a second reviewer evaluated data extraction of all pape 39 completed by one reviewer (DGK), whilst a second reviewer evaluated data extraction of all papers for correctness (JN). The data extraction tool was initially developed for this research protocol and was later refined b 40 extraction tool was initially developed for this research protocol and was later refined based upon the findings of the search results. This was not based on an existing tool, and items were selected based on discussion 41 results. This was not based on an existing tool, and items were selected based on discussion within the research team. Data from
42 each study included: (1) year of publication, (2) study aims and/or hypotheses, (3) stu 42 each study included: (1) year of publication, (2) study aims and/or hypotheses, (3) study location (i.e., country, recruiting hospital), (4) number of patients, (5) patient characteristics (i.e., years recruited, diagno 43 hospital), (4) number of patients, (5) patient characteristics (i.e., years recruited, diagnoses, treatments, cognitive outcomes, age at diagnosis/MRI/neuropsychological evaluation), and (6) statistical analyses. diagnosis/MRI/neuropsychological evaluation), and (6) statistical analyses.

45 We had initially registered our intention to assess the validity of the included studies using the Transparent Reporting of a
46 multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines; h 46 multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines; however, these were deemed
47 unsuitable given that none of the studies reported using predictive modelling in their approach. Ins 47 unsuitable given that none of the studies reported using predictive modelling in their approach. Instead, studies were reviewed (by DGK) using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) c

18 DGK) using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) checklist [45, 46], a checklist for
19 assessing reporting quality specific to the domain of oncology. Whilst designed for marker/ass

49 assessing reporting quality specific to the domain of oncology. Whilst designed for marker/assay testing, the domain relevance 50 and prognostic nature renders this a relevant tool. We considered the MRI measures as the

50 and prognostic nature renders this a relevant tool. We considered the MRI measures as the 'marker' under investigation and the neuropsychological assessment as 'endpoints' for the purposes of the tool.

neuropsychological assessment as 'endpoints' for the purposes of the tool.

²Figure 1. PRISMA flow diagram

medRxiv preprint doi: https://doi.org/10.1101/2024.01.12.24301212; this version posted January 13, 2024. The copyright holder for this preprint
(which was not certified by peer review) is the author/tunder, who has granted The copyright holder for this preprint holder for this version posted January 13, 2024. The copyright holder for this preprint the copyright index is the copyright of the copyright of the copyright in the copyright in the who has granted by perfact in the authorycle and has granted medRxix a license to display the prepriation in perpetuity. . [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

> 2 3

⁸⁴**Results**

- 85 After reviewing titles and abstracts, 162 records were selected (see Fig1), and 153 full-text articles were assessed for eligibility.
86 Of those, 4 were included. Manual reference and citation checking of these selecte
- 86 Of those, 4 were included. Manual reference and citation checking of these selected articles (and identified literature reviews deemed to be relevant), identified no additional studies. Detailed information about the in
- deemed to be relevant), identified no additional studies. Detailed information about the included studies can be found in Table 2.

88 **Study characteristics and reporting quality**
89 Many studies were excluded because the M

- 89 Many studies were excluded because the MRI did not precede neuropsychological assessment (for instance because of the
80 matched timepoints of neuroimaging acquisition and test assessment), thus not defining them as 'pr
- 90 matched timepoints of neuroimaging acquisition and test assessment), thus not defining them as 'predictive' studies. In a small number of cases, the text was ambiguous to the order of testing (i.e., [47-50]), but did no
- 91 number of cases, the text was ambiguous to the order of testing (i.e., [47-50]), but did not refer to prediction, and thus were not included.
- included.
- 93 For the selected studies, sample sizes were small and ranged between n=7 and n=22. The most common tumour type across studies was medulloblastoma (n=35), then astrocytoma (n=17) with relatively few ependymoma and choro
- 94 studies was medulloblastoma (n=35), then astrocytoma (n=17) with relatively few ependymoma and choroid plexus papilloma (n=
95 3 & 1 respectively). Age at diagnosis across the studies ranged from 2.2 years to 15.6 (bas
- 95 $\,$ 3 & 1 respectively). Age at diagnosis across the studies ranged from 2.2 years to 15.6 (based on ranges and inter quartile range (IQR)). All studies selected associative statistical approaches (i.e., correlational
-
- 96 (IQR)). All studies selected associative statistical approaches (i.e., correlational analyses).
97 Using the REMARK checklist, studies were assessed against each reporting item (*Item* 97 Using the REMARK checklist, studies were assessed against each reporting item (*Item 1-20*), and here we report items where reporting was limited across the studies (*i.e.* one or less studies reported the item). No stu
- 98 reporting was limited across the studies (i.e. one or less studies reported the item). No studies gave a rationale for sample size
99 (Item 10, 0/4 studies), likely due to the limited samples in each study, however it w
- 99 (Item 10, 0/4 studies), likely due to the limited samples in each study, however it was unclear as to whether these were the entirety
90 of eligible patients within the given time frame (as only 1 study gave a full acc
- 00 of eligible patients within the given timeframe (as only 1 study gave a full accounting of the flow of patients in the study, *Item 12*,
1/4 studies) In terms of "Analysis and presentation", studies performed poorly fo 011 1/4 studies) In terms of "Analysis and presentation", studies performed poorly for a number of items (*Item 15, 17, 18, all 0/4 with* 12 no studies completing the item to be reported). Firstly, no study presented an ef
- 021 no studies completing the item to be reported). Firstly, no study presented an effect size for the predictive analysis (*Item 15*, 0/4
13 studies). Further, included studies did not conduct analysis of added value, inc
- 03 studies). Further, included studies did not conduct analysis of added value, including the MRI marker and 'standard prognostic variables' which are established (*Item* 17, 0/4 studies) nor sensitivity analysis/validatio
- variables' which are established (*Item* 17, 0/4 studies) nor sensitivity analysis/validation.

⁰⁵**White Matter (WM) predictors**

- 06 Of the studies assessed, three utilised diffusion tensor imaging (DTI) to image white matter as a predictor of outcomes. Liguoro et al. measured the fractional anisotropy (FA) and volumetry of spinocerebellar (SC), dent
- 07 al. measured the fractional anisotropy (FA) and volumetry of spinocerebellar (SC), dentorubrothalamocortical (DRTC) and

08 corticopontocerebellar tracts (frontopontocerebellar (FPC), parieto-pontocerebellar (PPC), occi
- 08 corticopontocerebellar tracts (frontopontocerebellar (FPC), parieto-pontocerebellar (PPC), occipitopontocerebellar (OPC), and
09 temporo-pontocerebellar (TPC)) [51]. Significant relationships were found between tracts r
- 09 temporo-pontocerebellar (TPC)) [51]. Significant relationships were found between tracts relevant to cerebellar connectivity, and
10 the Developmental Neuropsychology Assessment (NEPSY) and full-scale IQ (FSIQ) measured
- 10 the Developmental Neuropsychology Assessment (NEPSY) and full-scale IQ (FSIQ) measured approximately 5 months later [51].
11 Specifically, FSIQ correlated significantly with spherical and planar indices of the right PPC
- 11 Specifically, FSIQ correlated significantly with spherical and planar indices of the right PPC (r=-1, p=0.017 and r=0.886, p=0.033), with increases to planar index and decreases in spherical index associated with IQ [51
- 12 p=0.033), with increases to planar index and decreases in spherical index associated with IQ [51]. Liguoro et al. also found
13 significant correlations between specific fibre tract characteristics and tasks measuring a
- 13 significant correlations between specific fibre tract characteristics and tasks measuring attention, memory, sensorimotor, social
14 perception, and visuospatial processing domains. However, only visuospatial processing
- 14 perception, and visuospatial processing domains. However, only visuospatial processing showed convergent validity with
15 significant correlations across two different tasks measuring this same domain [51]. In this stud
- 15 significant correlations across two different tasks measuring this same domain [51]. In this study, the bilateral PPC and SC tracts were most commonly correlated with the neuropsychology tasks [51].
-
- 16 were most commonly correlated with the neuropsychology tasks [51].
17 Partanen et al., used MRI from the treatment period 3 months after 17 Partanen et al., used MRI from the treatment period 3 months after diagnosis (including during and after treatment) to predict
18 change in intellectual functioning over a 36 month period after diagnosis. A significant
- 18 change in intellectual functioning over a 36 month period after diagnosis. A significant reduction in FSIQ over time was found but
19 this was not related to diffusion measures (FA, mean diffusivity (MD), radial diffusi
- 19 this was not related to diffusion measures (FA, mean diffusivity (MD), radial diffusivity (RD) and axial diffusivity (AD)) for the 20 cortical spinal tract (CST), inferior fronto-occipital fasciculus (IFOF), inferior lo
- 20 cortical spinal tract (CST), inferior fronto-occipital fasciculus (IFOF), inferior longitudinal fasciculus (ILF), optic radiations (OR), and uncinate fasciculus (UF) [52]. Partanen et al. did however show that declines
- 21 and uncinate fasciculus (UF) [52]. Partanen et al. did however show that declines over time in processing speed index, observed 22 only in a subgroup of patients experiencing local therapy (i.e., focal radiation) versus
- 22 only in a subgroup of patients experiencing local therapy (i.e., focal radiation) versus cranial spinal radiation, was predicted by
23 baseline anisotropy in left inferior fronto-occipital fascicle (IFOF), with lower FA
- 23 baseline anisotropy in left inferior fronto-occipital fascicle (IFOF), with lower FA being related to greater decline [52]. Neither patient groups showed a difference in the left IFOF for diffusions measures compared to
- patient groups showed a difference in the left IFOF for diffusions measures compared to controls.
- 25 Riggs et. al. [53] utilised chronically acquired MRI (approximately 5 years post diagnosis) investigated correlations between 26 whole brain WM volume, FA of both the left and right UF and the general memory index of th 26 whole brain WM volume, FA of both the left and right UF and the general memory index of the CMS (in a subset of n=10
27 patients, outcomes measured between 2 and 19 months after MRI). Only FA of the left UF was signific 27 patients, outcomes measured between 2 and 19 months after MRI). Only FA of the left UF was significantly related to memory $(R=.64, p=.045)$, not the right uncinate fasciculus or total WM volume (as measured by structural 28 (R=.64, p=.045), not the right uncinate fasciculus or total WM volume (as measured by structural MRI), with increased FA related to increases in memory performance. The volume of the PPC tract also positively correlate 29 to increases in memory performance. The volume of the PPC tract also positively correlated with memory performance (R=.71, $p=0.045$) in Parten's study [52].
- $p=.045$) in Parten's study [52].
-
- 31 Strength of correlational relationship between indices of white matter integrity and neuropsychological outcome were large (according to Cohen's criteria) ranging from $|r|=64$ $|r|=1$. However, the very limited sample s 32 (according to Cohen's criteria) ranging from $|r|=64$ - $|r|=1$. However, the very limited sample sizes (n=10 & n=7) from which these were drawn gives reason for concern over the interpretation of these estimates.
- 33 these were drawn gives reason for concern over the interpretation of these estimates.
34 Grey Matter (GM) predictors
- ³⁴**Grey Matter (GM) predictors**

-
- 35 In Riggs et. al., No correlation was found between total GM volume or left hippocampus with the general memory index of the CMS, but the right hippocampal volume, measured at a chronic timepoint, showed significant posi
- 36 CMS, but the right hippocampal volume, measured at a chronic timepoint, showed significant positive correlation with memory
37 outcomes 2-19 months after MRI (R=.71, p=.02) [53]. It is important to note in this study, 37 outcomes 2-19 months after MRI ($R=.71$, $p=.02$) [53]. It is important to note in this study, that the right hippocampus, rather than the GM volume and left hippocampus, was significantly smaller in the patient group co
- the GM volume and left hippocampus, was significantly smaller in the patient group compared to healthy controls.

³⁹**Lesion predictors**

40 Zilli et. al. [54] used a lesion-symptom mapping approach, to investigate the overlap of lesions in children with versus without psychological impairment. The lesions investigated where tumour lesions, frontal insertion

- 41 psychological impairment. The lesions investigated where tumour lesions, frontal insertion of ventriculoperitoneal drainages and
42 ventricular volumes as drawn on the $T1w$ MRI. They found the greatest tumour lesion o
- 42 ventricular volumes, as drawn on the T1w MRI. They found the greatest tumour lesion overlap and therefore greatest damage was
43 found in median cerebellar, specifically paravermal and vermal regions. Begions of interes
- 43 found in median cerebellar, specifically paravermal and vermal regions. Regions of interest for the lateral ventricles also overlapped in impaired children, suggesting hydrocephalus as additional cause of future impairm
- overlapped in impaired children, suggesting hydrocephalus as additional cause of future impairment.

⁴⁵**Meta-analysis**

- 16 Despite registering our intention, reviewed studies were not of sufficient quality to conduct any form of meta-analysis due to varying measurement strategies, gaps in reported descriptive variables, and low power.
- varying measurement strategies, gaps in reported descriptive variables, and low power.

Table 2.

8

N.B. PA = Pilocytic Astrocytoma, MB = Medulloblastoma, EP = Ependymoma, CT = Chemotherapy, CRT = Cranial Radiation Therapy, PT = Proton Therapy, NR = Not Reported, sMRI = structural MRI, dMRI = Diffusion MRI, VOI = Volume of Interest, FA = Fractional Anisotropy, MD = Medial Diffusivity, RD = Radial Diffusivity, AD = Axial Diffusivity, Med. = Median, BVL=Battery for the Assessment of Language in Children aged 4-12, CMS = Children's Memory Scale, CSR=Cranial-Spinal Radiation

⁵¹**Discussion**

⁵²**Review of the State of Research** 53 The current systematic review aimed to investigate existing literature using MRI to predict later, and non-contemporaneous
54 neuropsychological outcomes in children with brain tumours. No studies reviewed here set out 54 neuropsychological outcomes in children with brain tumours. No studies reviewed here set out the rationale for and aimed to
55 predict future outcomes using model development and validation approaches. The lack of scien 55 predict future outcomes using model development and validation approaches. The lack of scientific attention given to this topic is
56 surprising given the dearth of literature advocating for such research. The papers id 56 surprising given the dearth of literature advocating for such research. The papers identified and reviewed here, did in fact conduct 57 analyses to this effect, but only due to the fortuitous nature of the selected time 57 analyses to this effect, but only due to the fortuitous nature of the selected timepoints, and intervals between the activities of MRI
58 scanning and neuropsychological testing. Despite an extensive search strategy, ev 58 scanning and neuropsychological testing. Despite an extensive search strategy, evidence with which to answer the current research
59 question was extremely limited, with the major finding being a severe lack of studies 59 question was extremely limited, with the major finding being a severe lack of studies in this area. The primary result of the review
50 must therefore be viewed as a need for further research in this very important rese ⁶⁰must therefore be viewed as a need for further research in this very important research area, with study designs that directly tackle

the need for outcome prediction in these cohorts.

52 The reason for this brevity of research in this field is unclear. Whilst our systematic search strategy was extensive, there were also difficulties in identifying papers due to poor reporting practices. For instance, fo

63 difficulties in identifying papers due to poor reporting practices. For instance, for some of the studies where the full text was
64 assessed, the timing of MRI in relation to assessment was ambiguous or unclear [47-50,

54 assessed, the timing of MRI in relation to assessment was ambiguous or unclear [47-50, 55]. Factors affecting the number of research articles in this area could include previous focus on survival, where increasing survi

- 55 research articles in this area could include previous focus on survival, where increasing survival rates are now placing a greater need for research on late effects. It is important to also consider that neurocognitive 56 need for research on late effects. It is important to also consider that neurocognitive effects are also only one of many potential 157 late effects experienced by this population [56, 57].
- late effects experienced by this population [56, 57].

68 Research in this area may also be impacted by the availability of clinical data with which to carry out this research. For children with pediatric brain tumours, there is an abundance of clinical MRI, with medical imagi ⁵⁹with pediatric brain tumours, there is an abundance of clinical MRI, with medical imaging required for vital for tumour detection
⁷⁰ and diagnosis, surgical and radiotherapy planning, and monitoring of treatment resp 70 and diagnosis, surgical and radiotherapy planning, and monitoring of treatment response and recurrence of disease. But this is not
71 necessarily echoed in access to neurocognitive assessment – testing is performed base 71 necessarily echoed in access to neurocognitive assessment – testing is performed based upon clinical need or clinical trial protocol
72 for instance, and thus this limits available retrospective datasets. This data, als 72 for instance, and thus this limits available retrospective datasets. This data, also comes from a heterogeneous cohort, with these children facing heterogeneous brain injuries as a result of their disease and treatment. 73 children facing heterogenous brain injuries as a result of their disease and treatment. Identifying homogenous patient groups
74 inevitably results in the smaller sample sizes seen in the current studies. Overall, these 74 inevitably results in the smaller sample sizes seen in the current studies. Overall, these factors are liable to impact the quantity of research studies in this field. research studies in this field.

76 Whilst number of studies was limited, the quality of existing studies was also a significant issue. In the reporting quality assessment (using the REMARK checklist [45, 46]) identified studies did not meet important cri 77 assessment (using the REMARK checklist [45, 46]) identified studies did not meet important criteria for development of prognostic markers. Specifically, studies failed to conduct additional analyses necessary for this d 78 prognostic markers. Specifically, studies failed to conduct additional analyses necessary for this development, such as sensitivity
79 or 'added-value' analyses – although this was likely due to limited sample sizes, th 79 or 'added-value' analyses – although this was likely due to limited sample sizes, therefore lacking statistical power necessary for
30 these additional analyses. Studies are typically involving "retrospective, monocentr 80 these additional analyses. Studies are typically involving "retrospective, monocentric study investigating a pediatric disease with
81 low annual incidence" [54] however future work will require larger sample sizes than 81 low annual incidence" [54] however future work will require larger sample sizes than those of the studies presented here. To note,
82 the checklist comments on a number of items pertaining to model building and multivar 82 the checklist comments on a number of items pertaining to model building and multivariate analyses, which were not conducted in the current studies. the current studies.

84 Overall, the findings from the reviewed research are limited – they have limited sample sizes and are rated as low quality in terms
85 of prediction studies. Without proper validation and replication, the quality and im 85 of prediction studies. Without proper validation and replication, the quality and impact of any conclusions must be viewed as
86 limited and/or potentially spurious. However, the findings are briefly discussed here in 86 limited and/or potentially spurious. However, the findings are briefly discussed here in terms of wider literature. This should be seen in the context of guiding hypothesis-driven future research and/or promoting future 87 seen in the context of guiding hypothesis-driven future research and/or promoting future validation and/or replication of these findings. findings.

⁸⁹**Summary of Findings of Reviewed Studies**

⁹⁰*Cerebellar Damage*: Given common posterior fossa presentation in pediatric brain tumours, it is unsurprising that studies 91 in this review a-priori selected regions of interest within cerebellar structures and related fibre projections from this region.
92 Damage to these circuits predicted outcomes [51], with lesions to the median cerebella 92 Damage to these circuits predicted outcomes [51], with lesions to the median cerebellar regions common in cognitively impaired
93 patients [54]. Studies of contemporaneous MRI and neuropsychology measures have found sim 93 patients [54]. Studies of contemporaneous MRI and neuropsychology measures have found similar. Horská and colleagues [58] found a decrease in vermis volumes over a 6-month period were significantly related to radiation 94 found a decrease in vermis volumes over a 6-month period were significantly related to radiation dose, and final volume after this
95 period related to neuropsychological measures of motor speed. Significant recent evid 95 period related to neuropsychological measures of motor speed. Significant recent evidence suggests that the posterior cerebellar
96 lobes are key in maintain cognitive performance [59], and animal models suggest that in For lobes are key in maintain cognitive performance [59], and animal models suggest that intact cerebellar activity is required to $\overline{37}$ enable typical developmental trajectories of cognitive abilities (in mice) [60]. 97 enable typical developmental trajectories of cognitive abilities (in mice) [60]. Essentially, the cerebellum plays as an integral node
98 in many distributed neural circuits that underpin multiple cognitive functions [6 98 in many distributed neural circuits that underpin multiple cognitive functions [61, 62]. Radical cerebellar resection has also been
99 associated with extensive WM microstructure changes across the brain [63]. Overall, 99 associated with extensive WM microstructure changes across the brain [63]. Overall, it is unsurprising that damage to cerebellar regions (through injury and treatment effects) may lead to multiple cognitive morbidities. regions (through injury and treatment effects) may lead to multiple cognitive morbidities.

11 *WM damage*: Riggs, Bouffet [53] argued that global measures of WM may be indicative of general injury and thus
12 correlate well with general ability, however, integrity of discrete tracts (such as the UF) may be a bet 02 correlate well with general ability, however, integrity of discrete tracts (such as the UF) may be a better predictor of specific
03 cognitive abilities – in this case memory. Previous reviews of cross-sectional researc 03 cognitive abilities – in this case memory. Previous reviews of cross-sectional research suggests a model where disorganised WM
04 microstructure is related to poorer cognitive abilities, especially processing speed and microstructure is related to poorer cognitive abilities, especially processing speed and memory deficits [22], by indicting that this 10

¹ 35 'damage-related impairment' is established early, and therefore WM microstructure is a potential biomarker to predict later
¹ 16 impairment. Both preclinical and patient studies suggest a loss of both GM and WM vo 06 impairment. Both preclinical and patient studies suggest a loss of both GM and WM volume, and failure of normal WM gain in
07 pediatric brain tumour survivors [15]. There are multiple mechanisms of WM damage; hydrocepha 07 pediatric brain tumour survivors [15]. There are multiple mechanisms of WM damage; hydrocephalous having direct neurotoxic

18 effects on periventricular WM due to decreased perfusion and oedema [64] or intragenic effec 08 effects on periventricular WM due to decreased perfusion and oedema [64] or intragenic effect of adjunct therapy (chemo and radiotherapy) as measurable by reduced volume and alterations to microstructural properties and 09 radiotherapy) as measurable by reduced volume and alterations to microstructural properties and failure of expected WM
10 development [49, 65]. WM damage is likely non-transient, in non-irradiated patients 15 years afte 10 development [49, 65]. WM damage is likely non-transient, in non-irradiated patients 15 years after diagnosis, FA measures are
11 reduced and are associated with impaired cognitive flexibility [66]. What is apparent is t 11 reduced and are associated with impaired cognitive flexibility [66]. What is apparent is that, across treatment and disease effects,
12 the subsequent WM injury is relevant to poor outcomes, including emotion, cognition

the subsequent WM injury is relevant to poor outcomes, including emotion, cognition, and behaviour [13, 49, 67].

13 **Recommendations for Future Research**
14 *Limited longitudinal studies*

¹⁴*Limited longitudinal studies*

15 The biggest limitation of the current research field is the lack of longitudinal research answering this research question. Whilst there have been multiple studies understanding the contemporaneous neuroanatomical subst 16 there have been multiple studies understanding the contemporaneous neuroanatomical substrates of poor neuropsychological
17 outcomes in pediatric brain tumours, from acutely post treatment to very long-term survivors, t 17 outcomes in pediatric brain tumours, from acutely post treatment to very long-term survivors, these have not translated into
18 similarly large body of work understanding long-term risk (as highlighted by our findings) 18 similarly large body of work understanding long-term risk (as highlighted by our findings) of cognitive morbidity. Further longitudinal research is needed to assess whether the contemporaneous neuroanatomical substrates 19 longitudinal research is needed to assess whether the contemporaneous neuroanatomical substrates of long-term impairment are in 20 fact predictive in the context of longitudinal studies. fact predictive in the context of longitudinal studies.

21 These longitudinal studies would also provide an opportunity to disentangle the developmental and age-related effects on this prediction-task. For several of the measures highlighted in this review (FA/MD etc.) there ar 22 prediction-task. For several of the measures highlighted in this review (FA/MD etc.) there are known developmental trajectories
[68] which will necessarily interact with disease-related changes. There is also likely to 23 [68] which will necessarily interact with disease-related changes. There is also likely to be unique effects of brain insult, across tumour growth, and treatment related injury at different ages, resulting in varying le 24 tumour growth, and treatment related injury at different ages, resulting in varying levels of long-term impairments [69]. The field
25 will need to rely upon longitudinal studies (with sufficient sample size/statistical 25 will need to rely upon longitudinal studies (with sufficient sample size/statistical power) that can sufficiently disentangle these interactions. interactions.

²⁷*Study Variables: Timing*

28 There are two important timings to consider for the field moving forward to truly provide the most clinical impact moving
29 forward. Firstly, the time between 'predictive' MRI and neurocognitive assessment. Across the 29 forward. Firstly, the time between 'predictive' MRI and neurocognitive assessment. Across the reported studies, this was extremely short, limited to less than a year in most cases. This is potentially less useful clinic 30 extremely short, limited to less than a year in most cases. This is potentially less useful clinically, where predictions of outcomes 31 further out (2 years, 5 years etc) may be of greater impact, especially in cases w 31 further out (2years, 5years etc) may be of greater impact, especially in cases where the gap between them and their peers grow with the failure to 'keep up'. However, given that the reported studies did not set out to d 32 with the failure to 'keep up'. However, given that the reported studies did not set out to develop prognostic models, this is unsurprising, and unfair to judge them so. The second important timing to consider is the tim 33 unsurprising, and unfair to judge them so. The second important timing to consider is the time between diagnosis and 'predictive' MRI. In order for this predictive information to be useful for patient management and tre 34 MRI. In order for this predictive information to be useful for patient management and treatment planning, this interval needs to be short, especially given the urgency under which these patients need to receive potentia

35 short, especially given the urgency under which these patients need to receive potentially life-saving care.
36 There is no consensus on the optimal timing of MR imaging to use for predictive purposes. Selection of v 36 There is no consensus on the optimal timing of MR imaging to use for predictive purposes. Selection of which MRI is likely to be most predictive (in terms of reliability, accuracy etc.) will not be trivial for future re ³⁷most predictive (in terms of reliability, accuracy etc.) will not be trivial for future research. There is **s**ignificant evidence to 38 suggest that the treatment effects of injury are damaging to the still-developing brain and thus post treatment MRI may hold the complete picture of brain structural damage which lays the scaffold for future cognitive i 39 complete picture of brain structural damage which lays the scaffold for future cognitive impairment. These scans may however
30 come much later in the disease course and, as the timing of the MRI used for prediction inc 40 come much later in the disease course and, as the timing of the MRI used for prediction increases further from the diagnostic scan,
41 it is increasingly possible that the outcome of interest (cognitive morbidities) has ⁴¹it is increasingly possible that the outcome of interest (cognitive morbidities) has already presented, and thus prediction is not
⁴²useful (as the observation and/or measurement of the presenting difficulties is inh 12 useful (as the observation and/or measurement of the presenting difficulties is inherently the best predictor at that time point).
13 There is also the rationale of aiming for earliest prediction possible, to best enabl There is also the rationale of aiming for earliest prediction possible, to best enable early neuropsychological intervention to support better outcomes for these children. These children undergo MRI scanning at a number of 44 support better outcomes for these children. These children undergo MRI scanning at a number of timepoints in their disease
45 course (e.g. diagnostic imaging, pre- and post-surgical evaluation, progression monitoring et 45 course (e.g. diagnostic imaging, pre- and post-surgical evaluation, progression monitoring etc), and so there is significant data for
46 potential retrospective studies to investigate effect of MRI timing on prediction. 46 potential retrospective studies to investigate effect of MRI timing on prediction. Direct comparisons between models using MRI
47 from different timepoints will be meaningful to elicit after which events (i.e., diagnosi 47 from different timepoints will be meaningful to elicit after which events (i.e., diagnosis, tumour growth, treatment etc.) damage
48 has been sufficient to indicate future cognitive morbidities. This will be challenging ⁴⁸has been sufficient to indicate future cognitive morbidities. This will be challenging due to potential differences in MRI scans
⁴⁹ between events (i.e., initial diagnostic MRI at a tertiary hospital versus post-trea between events (i.e., initial diagnostic MRI at a tertiary hospital versus post-treatment MRI at a specialist centre).

50 However, it is important to consider timing of both MRI and neuropsychological assessment in the framework of predicting
51 outcomes. There may be consolidation periods post-surgery that impact outcome measurement over 51 outcomes. There may be consolidation periods post-surgery that impact outcome measurement over time, and thus research also needs to be clear in the timing of outcome measurement and / or study endpoint. needs to be clear in the timing of outcome measurement and / or study endpoint.

⁵³*Added Value of MRI*

54 One limitation of the current state of the research literature in this field is that the added value of MRI in prediction has not been
55 established, above and beyond existing approaches. No reviewed studies assessed e

55 established, above and beyond existing approaches. No reviewed studies assessed existing risk factors in a multivariate analysis to test the relative contributions, and therefore added value, of early MRI in predicting

56 test the relative contributions, and therefore added value, of early MRI in predicting future neurobehavioral morbidities. However,
57 Partanen et. al. reported that none of the medical or treatment variables that they ⁵⁷Partanen et. al. reported that none of the medical or treatment variables that they tested predicted change in IQ scores over time

58 [52]. This is despite these medical variables (Neurological Predictor Scale and presence of cerebellar mutism syndrome)
59 predicting acute/contemporaneous neuropsychology outcomes, and MRI-derived measures of baseline 59 predicting acute/contemporaneous neuropsychology outcomes, and MRI-derived measures of baseline WM injury being
50 significantly related with outcomes [52]. This is limited evidence to support the incremental validity o

50 significantly related with outcomes [52]. This is limited evidence to support the incremental validity of MRI as a predictor of long-term outcomes. Future studies should ensure to test for unique and additional predicti ⁶¹long-term outcomes. Future studies should ensure to test for unique and additional predictive power offered by quantitative MRI

variables

⁶³*Study Variables: Approach to ROIs*

64 Across the studies reviewed here two conducted analyses in regions-of-interest (ROIs) directly related to sites of brain insult in these patients [51, 52], one in ROIs related to the cognitive comorbidity under investig 65these patients [51, 52], one in ROIs related to the cognitive comorbidity under investigation [53], and only one investigating
66 characteristics of the lesion itself [54]. This does not consider how the wider brain netw 66 characteristics of the lesion itself [54]. This does not consider how the wider brain network may be influenced by the brain tumour, and this information may explain/predict additional variance in outcomes. For instance ⁵⁷ tumour, and this information may explain/predict additional variance in outcomes. For instance, in paediatric neurological
⁵⁸ disorders/syndromes, differences in brain morphometry or connectivity have been found bey 68 disorders/syndromes, differences in brain morphometry or connectivity have been found beyond the site of pathology (i.e. paradiatric represents in the absence of frank pathology (i.e. mild paediatric TBI [71], MRI-negat 59 paediatric epilepsy [70]) or in the absence of frank pathology (i.e. mild paediatric TBI [71], MRI-negative epilepsy [72]).
70 Disconnectome symptom mapping, shows that non-homologous lesions to the same brain network c 70 Disconnectome symptom mapping, shows that non-homologous lesions to the same brain network can generate the same
71 cognitive sequalae in terms of deficits. [73]. Many compensatory and 'rerouting' models of functional b 71 cognitive sequalae in terms of deficits. [73]. Many compensatory and 'rerouting' models of functional brain activity post injury
72 suggest that regions beyond the focal lesion may explain some sparing of cognitive abil 72 suggest that regions beyond the focal lesion may explain some sparing of cognitive abilities (another important factor in predicting
73 endpoint neurobehavioral morbidities). These findings all show that disparate, diff 73 endpoint neurobehavioral morbidities). These findings all show that disparate, diffuse, and non-lesioned changes to the brain, including tissue which may be typically thought of as 'spared', could also explain variance 74 including tissue which may be typically thought of as 'spared', could also explain variance in neurobehavioral morbidities.
75 Connectivity approaches to MRI have shown utility in contemporaneous measurements of MRI and 75 Connectivity approaches to MRI have shown utility in contemporaneous measurements of MRI and neuropsychology [74, 75].
76 These neurobiological effects of injury beyond the focal lesion may provide further prognostic in 76 These neurobiological effects of injury beyond the focal lesion may provide further prognostic information towards the aim of a
77 predictive model, however, to test a greater number of regions larger sample sizes will 77 predictive model, however, to test a greater number of regions larger sample sizes will be necessary to accurately estimate
78 statistical models across many more ROIs. This highlights one of the key challenges for futu 78 statistical models across many more ROIs. This highlights one of the key challenges for future studies in this field being data collection. collection.

⁸⁰**Limitations of Review**

81 It should be noted that, despite an extensive search, no study explicitly investigated the research question of whether MRI could
82 be used for long term prediction of neurocognitive outcomes in pediatric brain tumour 82 be used for long term prediction of neurocognitive outcomes in pediatric brain tumour patients. Described studies were reviewed
83 here due to non-primary analyses which fulfilled inclusion criteria, and therefore it ma 83 here due to non-primary analyses which fulfilled inclusion criteria, and therefore it may be the case that other studies with such analyses may have been missed in the review process (for instance if these secondary ana 84 analyses may have been missed in the review process (for instance if these secondary analyses were not mentioned in the abstract). To address this, we erred on the side of caution in reviewing abstracts, using full-text 85 abstract). To address this, we erred on the side of caution in reviewing abstracts, using full-text review as a method to identify these relevant secondary analyses. these relevant secondary analyses.

87 **Conclusion**
88 As early as

88 As early as 2008, it was proposed that to truly balance the aggressiveness of treatment for childhood CNS tumours, against the relative quality of life due to cognitive impairment, an important factor is knowing the lik 89 relative quality of life due to cognitive impairment, an important factor is knowing the likelihood of any one individual and experiencing neurocognitive impairment [12]. This individualised risk is key in purported mod 90 experiencing neurocognitive impairment [12]. This individualised risk is key in purported models of monitoring and managing of neurocognitive functioning in children with brain tumours [76]. There has also been signific 91 neurocognitive functioning in children with brain tumours [76]. There has also been significant work in the field of pediatric brain
92 tumours proposing developmental cognitive neuroscience models of late effects in su 92 tumours proposing developmental cognitive neuroscience models of late effects in survivors [12, 22, 77, 78]. These models, built
93 on contemporaneous measures of cognition and brain development, alongside cross-sectio 93 on contemporaneous measures of cognition and brain development, alongside cross-sectional data, are inherently limited.
94 Knowing individualised risk of long-term cognitive morbidity ahead of time would have significan ⁹⁴Knowing individualised risk of long-term cognitive morbidity ahead of time would have significant clinical impact; to inform 95 clinical management, prioritise resources/support, and reduce uncertainty for families. Overall, there exists plenty clinical reasoning to prompt scientific enthusiasm and attention for this topic. reasoning to prompt scientific enthusiasm and attention for this topic.

97 However, despite these early calls for prediction, and models with which to guide these predictive studies, this systematic review
98 highlights that the number of truly predictive studies (requiring a period between pr ⁹⁸highlights that the number of truly predictive studies (requiring a period between predictive features and long-term outcomes) is 99 still limited. In conclusion, Given the increased number of adult survivors of childhood brain tumours, the poorer long-term
90 cognitive, educational and employment outcomes [10, 13, 14] and the significant burden this 00 cognitive, educational and employment outcomes [10, 13, 14] and the significant burden this represents to patients, families and
11 healthcare, work now needs to be completed to integrate predictive data into these mode 01 healthcare, work now needs to be completed to integrate predictive data into these models, which will expand their explanatory value and utility to clinical practice. This will be an important next step in delivering fu 02 value and utility to clinical practice. This will be an important next step in delivering further clinical impact for this patient group.
03 Given the great potential that MRI provides in investigating neurobiological e

03 Given the great potential that MRI provides in investigating neurobiological effects of disease and treatment at the individual-
14 level, the plethora of multimodal imaging available in these clinical populations and f

- 14 level, the plethora of multimodal imaging available in these clinical populations and finally the positive clinical benefit this could offer, there is exciting opportunities for this type of research. ⁰⁵offer, there is exciting opportunities for this type of research.
-

⁰⁷*Data Availability*

Data extracted from included studies is publicly available and found (in its entirety) in Table 2. Lists of reviewed studied, at each stage of the PRISMA flowchart are available from the authors upon reasonable request. stage of the PRISMA flowchart are available from the authors upon reasonable request.

¹⁰*Acknowledgments*

- 11 DGK is funded by a post-doctoral award from Aston University College of Health and Life Sciences, awarded to JN & DGK.
- 12

¹³**References**

- 14 1. Miller, K.D., L. Nogueira, T. Devasia, A.B. Mariotto, K.R. Yabroff, A. Jemal, J. Kramer, and R.L. Siegel,
15 Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin, 2022. 72(5): p. 409-436. 15 Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin, 2022. **72**(5): p. 409-436.
16 2. Phillips, S.M., L.S. Padgett, W.M. Leisenring, K.K. Stratton, K. Bishop, K.R. Krull, C.M. Alfar
- 16 2. Phillips, S.M., L.S. Padgett, W.M. Leisenring, K.K. Stratton, K. Bishop, K.R. Krull, C.M. Alfano, T.M.
17 Gibson, J.S. de Moor, D.B. Hartigan, G.T. Armstrong, L.L. Robison, J.H. Rowland, K.C. Oeffinger, and 17 Gibson, J.S. de Moor, D.B. Hartigan, G.T. Armstrong, L.L. Robison, J.H. Rowland, K.C. Oeffinger, and A.B.
18 Mariotto, *Survivors of childhood cancer in the United States: prevalence and burden of morbidity*. Cancer 18 Mariotto, *Survivors of childhood cancer in the United States: prevalence and burden of morbidity*. Cancer
19 Epidemiol Biomarkers Prev, 2015. **24**(4): p. 653-63.
- 19 Epidemiol Biomarkers Prev, 2015. **24**(4): p. 653-63.
20 3. American Cancer Society, *Cancer Facts & Figures* 2 ²⁰3. American Cancer Society, *Cancer Facts & Figures 2014*, A.C. Society, Editor. 2014, American Cancer
- 21 Society: Atlanta.
22 4. Ward, E., C. DeS ²²4. Ward, E., C. DeSantis, A. Robbins, B. Kohler, and A. Jemal, *Childhood and adolescent cancer statistics,* ²³*2014.* CA Cancer J Clin, 2014. **64**(2): p. 83-103.
- ²⁴5. Tabash, M.A., *Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in*
- ²⁵*the United States; SEER-based analysis.* J Neurol Sci, 2019. **400**: p. 148-152. ²⁶6. Ramaswamy, V. and M.D. Taylor, *Medulloblastoma: From Myth to Molecular.* J Clin Oncol, 2017. **35**(21): p.
- 27 2355-2363.
28 7. Gatta, G., G 287. Gatta, G., G. Zigon, R. Capocaccia, J.W. Coebergh, E. Desandes, P. Kaatsch, G. Pastore, R. Peris-Bonet, C.A.
29 Stiller, and E.W. Group, *Survival of European children and young adults with cancer diagnosed 1995-2002* 29 Stiller, and E.W. Group, *Survival of European children and young adults with cancer diagnosed 1995-2002.*
30 Eur J Cancer, 2009. 45(6): p. 992-1005.
- 30 Eur J Cancer, 2009. **45**(6): p. 992-1005.
31 8. Prevention, C.f.D.C., *Declines in cancer* ³¹8. Prevention, C.f.D.C., *Declines in cancer death rates among children and adolescents in the United States,*
- ³²*1999–2014*. 2016. 33 9. Wang, Y., A.P.Y. Liu, T.M. Lee, W.H.S. Wong, D.Y.T. Fong, L.K. Leung, M.M.K. Shing, D.T. Ku, G.C.
34 Chan, and W.W. Tso, *Neurobehavioral Impairment in Pediatric Brain Tumor Survivors: A Meta-Analysis*. 34 Chan, and W.W. Tso, *Neurobehavioral Impairment in Pediatric Brain Tumor Survivors: A Meta-Analysis.*
35 Cancers (Basel), 2022. **14**(13). 35 Cancers (Basel), 2022. **14**(13).
36 10. Maddrey, A.M., J.A. Bergeron.
- 36 10. Maddrey, A.M., J.A. Bergeron, E.R. Lombardo, N.K. McDonald, A.F. Mulne, P.D. Barenberg, and D.C.
37 Bowers, *Neuropsychological performance and quality of life of 10 year survivors of childhood* 37 Bowers, *Neuropsychological performance and quality of life of 10 year survivors of childhood* **38** medulloblastoma. J Neurooncol, 2005. **72**(3): p. 245-53. ³⁸*medulloblastoma.* J Neurooncol, 2005. **72**(3): p. 245-53.
- 39 11. Palmer, S.L., O. Goloubeva, W.E. Reddick, J.O. Glass, A. Gajjar, L. Kun, T.E. Merchant, and R.K. Mulhern,
30 Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis ⁴⁰*Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis.* 41 **Journal of Clinical Oncology, 2001. 19**(8): p. 2302-2308.
42 **12.** Askins, M.A. and B.D. Moore, 3rd, *Preventing neurocogn*
- 42 12. Askins, M.A. and B.D. Moore, 3rd, *Preventing neurocognitive late effects in childhood cancer survivors*. J
43 Child Neurol, 2008. **23**(10): p. 1160-71.
- 43 Child Neurol, 2008. **23**(10): p. 1160-71.
14 13. Lassaletta, A., E. Bouffet, D. Mabbott, a ⁴⁴13. Lassaletta, A., E. Bouffet, D. Mabbott, and A.V. Kulkarni, *Functional and neuropsychological late outcomes*
- ⁴⁵*in posterior fossa tumors in children.* Childs Nerv Syst, 2015. **31**(10): p. 1877-90. 14. Devine, K.A., S. Christen, R.L. Mulder, M.C. Brown, L.M. Ingerski, L. Mader, E.J. Potter, C. Sleurs, A.S.
17 Viola, S. Waern, L.S. Constine, M.M. Hudson, L.C.M. Kremer, R. Skinner, G. Michel, J. Gilleland Marcha 47 Viola, S. Waern, L.S. Constine, M.M. Hudson, L.C.M. Kremer, R. Skinner, G. Michel, J. Gilleland Marchak, F.S.M. Schulte, and G. International Guidelines Harmonization Group Psychological Late Effects, 48 F.S.M. Schulte, and G. International Guidelines Harmonization Group Psychological Late Effects,
19 Recommendations for the surveillance of education and employment outcomes in survivors of child ⁴⁹*Recommendations for the surveillance of education and employment outcomes in survivors of childhood,* ⁵⁰*adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cancer*
- ⁵¹*Guideline Harmonization Group.* Cancer, 2022. **128**(13): p. 2405-2419. ⁵²15. Al Dahhan, N.Z., E. Cox, B.J. Nieman, and D.J. Mabbott, *Cross-translational models of late-onset cognitive*
- ⁵³*sequelae and their treatment in pediatric brain tumor survivors.* Neuron, 2022. **110**(14): p. 2215-2241. ⁵⁴16. Hardy, K.K., M.M. Hudson, and K.R. Krull, *Life-Altering Consequences of Neurocognitive Impairment in*
- ⁵⁵*Survivors of Pediatric Cancer.* J Clin Oncol, 2021. **39**(16): p. 1693-1695. ⁵⁶17. Willard, V.W., K.S. Berlin, H.M. Conklin, and T.E. Merchant, *Trajectories of psychosocial and cognitive* ⁵⁷*functioning in pediatric patients with brain tumors treated with radiation therapy.* Neuro Oncol, 2019. **21**(5):
- 58 p. 678-685.
59 18. Sharkey, C. 59 18. Sharkey, C.M., L.L. Mullins, A.H. Clawson, A. Gioia, M.A.W. Hawkins, J.M. Chaney, K.S. Walsh, and K.K.
50 Hardy, *Assessing neuropsychological phenotypes of pediatric brain tumor survivors*. Psychooncology, 2021. ⁶⁰Hardy, *Assessing neuropsychological phenotypes of pediatric brain tumor survivors.* Psychooncology, 2021. 51 **30**(8): p. 1366-1374.
52 19. Major, N., N.A. Patel
- 6219. Major, N., N.A. Patel, J. Bennett, E. Novakovic, D. Poloni, M. Abraham, N.J. Brown, J.L. Gendreau, R.
53 Sahyouni, and J. Loya, *The Current State of Radiotherapy for Pediatric Brain Tumors: An Overview of I* 53 Sahyouni, and J. Loya, *The Current State of Radiotherapy for Pediatric Brain Tumors: An Overview of Post-*
54 *Radiotherapy Neurocognitive Decline and Outcomes.* J Pers Med, 2022. 12(7).
- ⁶⁴*Radiotherapy Neurocognitive Decline and Outcomes.* J Pers Med, 2022. **12**(7). ⁶⁵20. Ajithkumar, T., S. Price, G. Horan, A. Burke, and S. Jefferies, *Prevention of radiotherapy-induced* ⁶⁶*neurocognitive dysfunction in survivors of paediatric brain tumours: the potential role of modern imaging and*
- ⁶⁷*radiotherapy techniques.* Lancet Oncol, 2017. **18**(2): p. e91-e100. ⁶⁸21. Peterson, R.K. and T.Z. King, *A systemic review of pediatric neuropsychological outcomes with proton versus* ⁶⁹*photon radiation therapy: A call for equity in access to treatment.* J Int Neuropsychol Soc, 2022: p. 1-14.

- ⁷⁰22. Wauters, M., A. Uyttebroeck, L. De Waele, C. Sleurs, and S. Jacobs, *Neuroimaging Biomarkers and* ⁷¹*Neurocognitive Outcomes in Pediatric Medulloblastoma Patients: a Systematic Review.* Cerebellum, 2021.
- 72 **20**(3): p. 462-480.

73 23. Oyefiade, A., I. Pa 73 23. Oyefiade, A., I. Paltin, C.R. De Luca, K.K. Hardy, D.R. Grosshans, M. Chintagumpala, D.J. Mabbott, and
14 L.S. Kahalley, *Cognitive Risk in Survivors of Pediatric Brain Tumors*. J Clin Oncol, 2021. **39**(16): p. 1718 ⁷⁴L.S. Kahalley, *Cognitive Risk in Survivors of Pediatric Brain Tumors.* J Clin Oncol, 2021. **39**(16): p. 1718-
- 75 1726.
76 24. Palme ⁷⁶24. Palmer, S.L., *Neurodevelopmental impact on children treated for medulloblastoma: a review and proposed*
- ⁷⁷*conceptual model.* Dev Disabil Res Rev, 2008. **14**(3): p. 203-10. ⁷⁸25. Wolfe, K.R., A. Madan-Swain, and R.K. Kana, *Executive dysfunction in pediatric posterior fossa tumor* ⁷⁹*survivors: a systematic literature review of neurocognitive deficits and interventions.* Dev Neuropsychol,
- 80 2012. **37**(2): p. 153-75.

81 26. King, T.Z., A.S. Ailion. 81 26. King, T.Z., A.S. Ailion, M.E. Fox, and S.M. Hufstetler, *Neurodevelopmental model of long-term outcomes of adult survivors of childhood brain tumors*. Child Neuropsychol, 2019. **25**(1): p. 1-21. 82 adult survivors of childhood brain tumors. Child Neuropsychol, 2019. **25**(1): p. 1-21.
83 27. Marusak, H.A., A.S. Iadipaolo, F.W. Harper, F. Elrahal, J.W. Taub, E. Goldberg, and
- 83 27. Marusak, H.A., A.S. Iadipaolo, F.W. Harper, F. Elrahal, J.W. Taub, E. Goldberg, and C.A. Rabinak,
84 Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity ⁸⁴*Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity* ⁸⁵*framework to understanding cognitive, behavioral, and emotional outcomes.* Neuropsychol Rev, 2018. **28**(2):
- 36 p. 123-175.
37 28. King, A.A., 8728. King, A.A., K. Seidel, C. Di, W.M. Leisenring, S.M. Perkins, K.R. Krull, C.A. Sklar, D.M. Green, G.T.
88 Armstrong, L.K. Zeltzer, E. Wells, M. Stovall, N.J. Ullrich, K.C. Oeffinger, L.L. Robison, and R.J. Pack 88 Armstrong, L.K. Zeltzer, E. Wells, M. Stovall, N.J. Ullrich, K.C. Oeffinger, L.L. Robison, and R.J. Packer,
89 *Long-term neurologic health and psychosocial function of adult survivors of childhood* ⁸⁹*Long-term neurologic health and psychosocial function of adult survivors of childhood* ⁹⁰*medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study.* Neuro Oncol, 2017. **19**(5): p.
- 91 689-698.

92 29. de Ruiter 92 29. de Ruiter, M.A., R. van Mourik, A.Y. Schouten-van Meeteren, M.A. Grootenhuis, and J. Oosterlaan,
93 Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis. Dev N ⁹³*Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis.* Dev Med Child
- 94 Neurol, 2013. **55**(5): p. 408-17.

95 30. Nathan, P.C., S.K. Patel, K. Dil 95 30. Nathan, P.C., S.K. Patel, K. Dilley, R. Goldsby, J. Harvey, C. Jacobsen, N. Kadan-Lottick, K. McKinley, A.K.
96 Millham, I. Moore, M.F. Okcu, C.L. Woodman, P. Brouwers, F.D. Armstrong, and C. Children's Oncology 96 Millham, I. Moore, M.F. Okcu, C.L. Woodman, P. Brouwers, F.D. Armstrong, and C. Children's Oncology
97 Group Long-term Follow-up Guidelines Task Force on Neurocognitive/Behavioral Complications After 97 Group Long-term Follow-up Guidelines Task Force on Neurocognitive/Behavioral Complications After
98 Childhood, Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in ⁹⁸Childhood, *Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in* ⁹⁹*survivors of childhood cancer: a report from the Children's Oncology Group.* Arch Pediatr Adolesc Med,
- 00 2007. **161**(8): p. 798-806.

11 31. Krull, K.R., S. Minoshima 01 31. Krull, K.R., S. Minoshima, M. Edelmann, B. Morris, N.D. Sabin, T.M. Brinkman, G.T. Armstrong, L.L.
22 Robison, M.M. Hudson, and B. Shulkin, *Regional brain glucose metabolism and neurocognitive function* ⁰²Robison, M.M. Hudson, and B. Shulkin, *Regional brain glucose metabolism and neurocognitive function in* ⁰³*adult survivors of childhood cancer treated with cranial radiation.* J Nucl Med, 2014. **55**(11): p. 1805-10.
- 04 32. Carpentieri, S.C., D.P. Waber, S.L. Pomeroy, R.M. Scott, L.C. Goumnerova, M.W. Kieran, A.L. Billett, and
05 N.J. Tarbell, *Neuropsychological functioning after surgery in children treated for brain tumor*. Neurosurg ⁰⁵N.J. Tarbell, *Neuropsychological functioning after surgery in children treated for brain tumor.* Neurosurgery,
- 06 2003. **52**(6): p. 1348-56; discussion 1356-7.

133. Taiwo, Z., S. Na, and T.Z. King, *The Neuro* ⁰⁷33. Taiwo, Z., S. Na, and T.Z. King, *The Neurological Predictor Scale: A predictive tool for long-term core*
- ⁰⁸*cognitive outcomes in survivors of childhood brain tumors.* Pediatr Blood Cancer, 2017. **64**(1): p. 172-179. ⁰⁹34. Levitch, C.F., A.A. Holland, J. Bledsoe, S.Y. Kim, M. Barnett, S. Ramjan, and S.A. Sands, *Comparison of* ¹⁰*neuropsychological functioning in pediatric posterior fossa tumor survivors: Medulloblastoma, low-grade*
- 11 astrocytoma, and healthy controls. Pediatr Blood Cancer, 2022. **69**(2): p. e29491.
12 35. Micklewright, J.L., T.Z. King, R.D. Morris, and N. Krawiecki, *Quantifying pedial* ¹²35. Micklewright, J.L., T.Z. King, R.D. Morris, and N. Krawiecki, *Quantifying pediatric neuro-oncology risk*
- ¹³*factors: development of the neurological predictor scale.* J Child Neurol, 2008. **23**(4): p. 455-8. ¹⁴36. Papazoglou, A., T.Z. King, R.D. Morris, and N. Krawiecki, *Parent report of attention problems predicts later*
- 15 *adaptive functioning in children with brain tumors.* Child Neuropsychol, 2009. **15**(1): p. 40-52.
16 37. King, T.Z. and S. Na, *Cumulative neurological factors associated with long-term outcomes in a* ¹⁶37. King, T.Z. and S. Na, *Cumulative neurological factors associated with long-term outcomes in adult survivors*
- 17 of childhood brain tumors. Child Neuropsychol, 2016. **22**(6): p. 748-60.
18 38. Kautiainen, R.J., S.D. Na, and T.Z. King, *Neurological predictor scale i*. ¹⁸38. Kautiainen, R.J., S.D. Na, and T.Z. King, *Neurological predictor scale is associated with academic* ¹⁹*achievement outcomes in long-term survivors of childhood brain tumors.* J Neurooncol, 2019. **142**(1): p. 193-
- $\begin{array}{cc} 20 & 201. \\ 21 & 39. \end{array}$ Bae, ²¹39. Bae, D., V.V. Mlc, and C.E. Catsman-Berrevoets, *Preoperative prediction of postoperative cerebellar mutism* 22 *syndrome. Validation of existing MRI models and proposal of the new Rotterdam pCMS prediction model.*
23 Childs Nerv Syst, 2020. **36**(7): p. 1471-1480.
- 23 Childs Nerv Syst, 2020. **36**(7): p. 1471-1480.
24 40. Kesler, S.R., C. Sleurs, B.C. McDonald, S. D ²⁴40. Kesler, S.R., C. Sleurs, B.C. McDonald, S. Deprez, E. van der Plas, and B.J. Nieman, *Brain Imaging in*
- ²⁵*Pediatric Cancer Survivors: Correlates of Cognitive Impairment.* J Clin Oncol, 2021. **39**(16): p. 1775-1785. ²⁶41. Baker, S. and Y. Kandasamy, *Machine learning for understanding and predicting neurodevelopmental*
- ²⁷*outcomes in premature infants: a systematic review.* Pediatr Res, 2022: p. 1-7.

- ²⁸42. Li, X., X. Wang, L. Su, X. Hu, and Y. Han, *Sino Longitudinal Study on Cognitive Decline (SILCODE):* ²⁹*protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to*
- 30 mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open, 2019. **9**(7): p. e028188.
31 43. Page, M.J., J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. 31 43. Page, M.J., J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M.
32 Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hrobjartsson, M.M. Lalu, T 32 Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hrobjartsson, M.M. Lalu, T. Li,
33 E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. 33 E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. 34 Welch, P. Whiting, and D. Moher, *The PRISMA 2020 statement: an updated guideline for reporting* ³⁴Welch, P. Whiting, and D. Moher, *The PRISMA 2020 statement: an updated guideline for reporting*
- ³⁵*systematic reviews.* Syst Rev, 2021. **10**(1): p. 89. ³⁶44. Ostrom, Q.T., G. Cioffi, K. Waite, C. Kruchko, and J.S.J.N.-o. Barnholtz-Sloan, *CBTRUS statistical report:* ³⁷*primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018.* 2021.
- 38 **23**(Supplement_3): p. iii1-iii105.
39 45. McShane, L.M., D.G. Altman, W ³⁹45. McShane, L.M., D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark, *Reporting* ⁴⁰*recommendations for tumor marker prognostic studies (REMARK).* Journal of the National Cancer Institute,
- 11 2005. **97**(16): p. 1180-1184.
12 46. Sauerbrei, W., S.E. Taube, L ⁴²46. Sauerbrei, W., S.E. Taube, L.M. McShane, M.M. Cavenagh, and D.G. Altman, *Reporting Recommendations* ⁴³*for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.* J Natl Cancer
- 14 Inst, 2018. **110**(8): p. 803-811.

15 47. Aukema, E.J., M.W. Caan, N. 0 47. Aukema, E.J., M.W. Caan, N. Oudhuis, C.B. Majoie, F.M. Vos, L. Reneman, B.F. Last, M.A. Grootenhuis, and A.Y. Schouten-van Meeteren, White matter fractional anisotropy correlates with speed of processing an 46 and A.Y. Schouten-van Meeteren, *White matter fractional anisotropy correlates with speed of processing and motor speed in young childhood cancer survivors*. Int J Radiat Oncol Biol Phys, 2009. **74**(3): p. 837-43.
- ⁴⁷*motor speed in young childhood cancer survivors.* Int J Radiat Oncol Biol Phys, 2009. **74**(3): p. 837-43. ⁴⁸48. Mulhern, R.K., S.L. Palmer, W.E. Reddick, J.O. Glass, L.E. Kun, J. Taylor, J. Langston, and A. Gajjar, *Risks* ⁴⁹*of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss.*^J
- 50 Clin Oncol, 2001. **19**(2): p. 472-9.
51 49. Reddick, W.E., D.J. Taghipour, J.C 51 49. Reddick, W.E., D.J. Taghipour, J.O. Glass, J. Ashford, X.P. Xiong, S.J. Wu, M. Bonner, R.B. Khan, and H.M.
52 Conklin, *Prognostic Factors that Increase the Risk for Reduced White Matter Volumes and Deficits in* 52 Conklin, *Prognostic Factors that Increase the Risk for Reduced White Matter Volumes and Deficits in* 53 *Attention and Learning for Survivors of Childhood Cancers*. Pediatric Blood & Cancer, 2014. **61**(6): p. ⁵³*Attention and Learning for Survivors of Childhood Cancers.* Pediatric Blood & Cancer, 2014. **61**(6): p. 1074- 54 1079.
55 50. Tso, V
- 55 50. Tso, W.W.Y., E.S.K. Hui, T.M.C. Lee, A.P.Y. Liu, P. Ip, V. Vardhanabhuti, K.K.F. Cheng, D.Y.T. Fong, D.
56 D.H.F. Chang, F.K.W. Ho, K.M. Yip, D.T.L. Ku, D.K.L. Cheuk, C.W. Luk, M.K. Shing, L.K. Leung, P.L. 56 D.H.F. Chang, F.K.W. Ho, K.M. Yip, D.T.L. Ku, D.K.L. Cheuk, C.W. Luk, M.K. Shing, L.K. Leung, P.L.
57 Khong, and G.C. Chan, *Brain Microstructural Changes Associated With Neurocognitive Outcome in* 57 Khong, and G.C. Chan, *Brain Microstructural Changes Associated With Neurocognitive Outcome in* ⁵⁸ *Intracranial Germ Cell Tumor Survivors.* Front Oncol, 2021. **11**: p. 573798.
- ⁵⁸*Intracranial Germ Cell Tumor Survivors.* Front Oncol, 2021. **11**: p. 573798. 59 51. Liguoro, I., E. Passone, T. Zilli, M. Maieron, M.C. De Colle, M. Skrap, V. Dolcemascolo, G. Sommariva, P.
50 Cogo, and B. Tomasino, *Possible association between the integrity of cerebellar pathways and neurocogniti* ⁶⁰Cogo, and B. Tomasino, *Possible association between the integrity of cerebellar pathways and neurocognitive*
- ⁶¹*performance in children with posterior fossa tumors.* Pediatr Blood Cancer, 2020. **67**(9): p. e28538. 52. Partanen, M., E. Bouffet, S. Laughlin, D. Strother, J. Hukin, J. Skocic, K. Szulc-Lerch, and D.J. Mabbott,
53 Early changes in white matter predict intellectual outcome in children treated for posterior fossa tumors. ⁶³*Early changes in white matter predict intellectual outcome in children treated for posterior fossa tumors.* 54 Neuroimage Clin, 2018. **20**: p. 697-704.
55 53. Riggs, L., E. Bouffet, S. Laughlin, N. La
- 55 53. Riggs, L., E. Bouffet, S. Laughlin, N. Laperriere, F. Liu, J. Skocic, N. Scantlebury, F. Wang, N.J. Schoenhoff, D. Strother, J. Hukin, C. Fryer, D. McConnell, and D.J. Mabbott, Changes to memory structures in childr 56 D. Strother, J. Hukin, C. Fryer, D. McConnell, and D.J. Mabbott, *Changes to memory structures in children freated for posterior fossa tumors*. J Int Neuropsychol Soc, 2014. **20**(2): p. 168-80. ⁶⁷*treated for posterior fossa tumors.* J Int Neuropsychol Soc, 2014. **20**(2): p. 168-80.
- 58 54. Zilli, T., V. Dolcemascolo, E. Passone, M. Maieron, M.C. De Colle, M. Skrap, T. Ius, I. Liguoro, M. Venchiarutti, P. Cogo, and B. Tomasino, A multimodal approach to the study of children treated for p 59 Venchiarutti, P. Cogo, and B. Tomasino, *A multimodal approach to the study of children treated for posterior*
70 fossa tumor: *A review of the literature and a pilot study*. Clin Neurol Neurosurg, 2021. **207**: p. 10681
- ⁷⁰*fossa tumor: A review of the literature and a pilot study.* Clin Neurol Neurosurg, 2021. **207**: p. 106819. 71 55. Kline, C., S. Stoller, L. Byer, D. Samuel, J.M. Lupo, M.A. Morrison, A.M. Rauschecker, P. Nedelec, W. Faig, D.B. Dubal, H.J. Fullerton, and S. Mueller, An Integrated Analysis of Clinical, Genomic, and Imaging ⁷²D.B. Dubal, H.J. Fullerton, and S. Mueller, *An Integrated Analysis of Clinical, Genomic, and Imaging* ⁷³*Features Reveals Predictors of Neurocognitive Outcomes in a Longitudinal Cohort of Pediatric Cancer*
- ⁷⁴*Survivors, Enriched with CNS Tumors (Rad ART Pro).* Front Oncol, 2022. **12**: p. 874317.
- ⁷⁵56. Rey-Casserly, C. and T.J.C.o.i.p. Diver, *Late effects of pediatric brain tumors.* 2019. **31**(6): p. 789-796. ⁷⁶57. Alemany, M., R. Velasco, M. Simó, and J.J.N.-O.P. Bruna, *Late effects of cancer treatment: consequences for* ⁷⁷*long-term brain cancer survivors.* 2021. **8**(1): p. 18-30.
- 78 58. Horska, A., A. Laclair, M. Mohamed, C.T. Wells, T. McNutt, K.J. Cohen, M. Wharam, E.M. Mahone, and W.
79 Kates, Low cerebellar vermis volumes and impaired neuropsychologic performance in children treated for 79 Kates, *Low cerebellar vermis volumes and impaired neuropsychologic performance in children treated for* ³⁰ *brain tumors and leukemia.* AJNR Am J Neuroradiol, 2010. **31**(8): p. 1430-7.
- 80 *brain tumors and leukemia.* AJNR Am J Neuroradiol, 2010. **31**(8): p. 1430-7.
81 59. Hoang, D.H., A. Pagnier, K. Guichardet, F. Dubois-Teklali, I. Schiff, G. Lyard 81 59. Hoang, D.H., A. Pagnier, K. Guichardet, F. Dubois-Teklali, I. Schiff, G. Lyard, E. Cousin, and A. Krainik,
82 Cognitive disorders in pediatric medulloblastoma: what neuroimaging has to offer. J Neurosurg Pediatr, ⁸²*Cognitive disorders in pediatric medulloblastoma: what neuroimaging has to offer.* J Neurosurg Pediatr,
- 83 2014. **14**(2): p. 136-44.

84 60. Badura, A., J.L. Verpeu 84 60. Badura, A., J.L. Verpeut, J.W. Metzger, T.D. Pereira, T.J. Pisano, B. Deverett, D.E. Bakshinskaya, and S.S.
85 Wang, *Normal cognitive and social development require posterior cerebellar activity*. Elife, 2018. 7. ⁸⁵Wang, *Normal cognitive and social development require posterior cerebellar activity.* Elife, 2018. **7**.

- ⁸⁶61. Clark, S.V., E.S. Semmel, H.A. Aleksonis, S.N. Steinberg, and T.Z. King, *Cerebellar-Subcortical-Cortical*
- 87 Systems as Modulators of Cognitive Functions. Neuropsychol Rev, 2021. **31**(3): p. 422-446.
88 62. Schmahmann, J.D., *The cerebellum and cognition*. Neurosci Lett, 2019. **688**: p. 62-75.
- ⁸⁸62. Schmahmann, J.D., *The cerebellum and cognition.* Neurosci Lett, 2019. **688**: p. 62-75. 89 63. Gomes, C.A., K.M. Steiner, N. Ludolph, T. Spisak, T.M. Ernst, O. Mueller, S.L. Goricke, F. Labrenz, W. Ilg, N. Axmacher, and D. Timmann, Resection of cerebellar tumours causes widespread and functionally relevant 90 N. Axmacher, and D. Timmann, *Resection of cerebellar tumours causes widespread and functionally relevant* **31** white matter impairments. Hum Brain Mapp, 2021. **42**(6): p. 1641-1656.
- ⁹¹*white matter impairments.* Hum Brain Mapp, 2021. **42**(6): p. 1641-1656. 92 64. Moberget, T., S. Andersson, T. Lundar, B.J. Due-Tonnessen, A. Heldal, T. Endestad, and L.T. Westlye, *Long-*⁹³*term supratentorial brain structure and cognitive function following cerebellar tumour resections in*
- 94 childhood. Neuropsychologia, 2015. **69**: p. 218-31.
95 65. Witzmann, K., F. Raschke, and E.G.C. Troost, MR ⁹⁵65. Witzmann, K., F. Raschke, and E.G.C. Troost, *MR Image Changes of Normal-Appearing Brain Tissue after* ⁹⁶*Radiotherapy.* Cancers (Basel), 2021. **13**(7).
- ⁹⁷66. Billiet, T., I. Elens, C. Sleurs, A. Uyttebroeck, R. D'Hooge, J. Lemiere, and S. Deprez, *Brain Connectivity and* ⁹⁸*Cognitive Flexibility in Nonirradiated Adult Survivors of Childhood Leukemia.* J Natl Cancer Inst, 2018.
- 99 **110**(8): p. 905-913.

00 67. Raghubar, K.P., E.N ⁰⁰67. Raghubar, K.P., E.M. Mahone, K.O. Yeates, K.M. Cecil, M. Makola, and M.D. Ris, *Working memory and* ⁰¹*attention in pediatric brain tumor patients treated with and without radiation therapy.* Child Neuropsychol, **2017. 23**(6): p. 642-654.
 23 68. **Krogstud, S.K., A.M. Fig.**
- 036. Krogsrud, S.K., A.M. Fjell, C.K. Tamnes, H. Grydeland, L. Mork, P. Due-Tonnessen, A. Bjornerud, C.

24 Sampaio-Baptista, J. Andersson, H. Johansen-Berg, and K.B. Walhovd, Changes in white matter ⁰⁴Sampaio-Baptista, J. Andersson, H. Johansen-Berg, and K.B. Walhovd, *Changes in white matter* ⁰⁵*microstructure in the developing brain--A longitudinal diffusion tensor imaging study of children from 4 to*
- ⁰⁶*11years of age.* Neuroimage, 2016. **124**(Pt A): p. 473-486. ⁰⁷69. Jones, R.M. and S.S. Pattwell, *Future considerations for pediatric cancer survivorship: Translational* ⁰⁸*perspectives from developmental neuroscience.* Dev Cogn Neurosci, 2019. **38**: p. 100657.
- 09 70. Boutzoukas, E.M., J. Crutcher, E. Somoza, L.N. Sepeta, X. You, W.D. Gaillard, G.L. Wallace, and M.M.
10 Berl, Cortical thickness in childhood left focal epilepsy: Thinning beyond the seizure focus. Epilepsy Beh 10 Berl, *Cortical thickness in childhood left focal epilepsy: Thinning beyond the seizure focus.* Epilepsy Behav,
11 2020. **102**: p. 106825. 11 2020. **102**: p. 106825.
12 71 King D J K R Ellis
- 1271. King, D.J., K.R. Ellis, S. Seri, and A.G. Wood, *A systematic review of cross-sectional differences and*
13 *Ionaitudinal changes to the morphometry of the brain following paediatric traumatic brain injury* ¹³*longitudinal changes to the morphometry of the brain following paediatric traumatic brain injury.* 14 Neuroimage Clin, 2019. **23**: p. 101844.
15 72. Zelko, F.A., H.R. Pardoe, S.R. Blacksto
- ¹⁵72. Zelko, F.A., H.R. Pardoe, S.R. Blackstone, G.D. Jackson, and A.T. Berg, *Regional brain volumes and* ¹⁶*cognition in childhood epilepsy: does size really matter?* Epilepsy Res, 2014. **108**(4): p. 692-700.
- 17 13. Foulon, C., L. Cerliani, S. Kinkingnéhun, R. Levy, C. Rosso, M. Urbanski, E. Volle, and M. Thiebaut de
18 Schotten, Advanced lesion symptom mapping analyses and implementation as BCBtoolkit. Gigascience, 2 18 Schotten, *Advanced lesion symptom mapping analyses and implementation as BCBtoolkit.* Gigascience, 2018.
19 7(3): p. 1-17.
- 19
74. Sleurs, C., J. 2074. Sleurs, C., J. Blommaert, D. Batalle, M. Verly, S. Sunaert, R. Peeters, J. Lemiere, A. Uyttebroeck, and S.
21 Deprez, Cortical thinning and altered functional brain coherence in survivors of childhood sarcoma. Bra 21 Deprez, *Cortical thinning and altered functional brain coherence in survivors of childhood sarcoma*. Brain 22 Imaging Behav, 2021. **15**(2): p. 677-688. 22 Imaging Behav, 2021. **15**(2): p. 677-688.
23 75. Sleurs, C., S. Jacobs, S.J. Counsell, D. Cl
- 23 75. Sleurs, C., S. Jacobs, S.J. Counsell, D. Christiaens, J.D. Tournier, S. Sunaert, K. Van Beek, A. Uyttebroeck, S. 24 Deprez, D. Batalle, and J. Lemiere, *Brain network hubs and cognitive performance of survivors of c* ²⁴Deprez, D. Batalle, and J. Lemiere, *Brain network hubs and cognitive performance of survivors of childhood*
- ²⁵*infratentorial tumors.* Radiother Oncol, 2021. **161**: p. 118-125. ²⁶76. Jacola, L.M., M. Partanen, J. Lemiere, M.M. Hudson, and S. Thomas, *Assessment and Monitoring of*
- ²⁷*Neurocognitive Function in Pediatric Cancer.* J Clin Oncol, 2021. **39**(16): p. 1696-1704. ²⁸77. Ailion, A.S., T.Z. King, L. Wang, M.E. Fox, H. Mao, R.M. Morris, and B. Crosson, *Cerebellar Atrophy in* 29
Adult Survivors of Childhood Cerebellar Tumor. **J Int Neuropsychol Soc, 2016. 22**(5): p. 501-11.
30 78. Palmer, S.L., J.O. Glass, Y. Li, R. Ogg, I. Qaddoumi, G.T. Armstrong, K. Wright, C. Wetmore, A
- 3078. Palmer, S.L., J.O. Glass, Y. Li, R. Ogg, I. Qaddoumi, G.T. Armstrong, K. Wright, C. Wetmore, A. Broniscer, A. Gajjar, and W.E. Reddick, White matter integrity is associated with cognitive processing in patients treat 31 A. Gajjar, and W.E. Reddick, *White matter integrity is associated with cognitive processing in patients treated for a posterior fossa brain tumor.* Neuro Oncol, 2012. **14**(9): p. 1185-93.
- ³²*for a posterior fossa brain tumor.* Neuro Oncol, 2012. **14**(9): p. 1185-93.